Undisclosed European Country Orders 440,000 Smallpox and Mpox Vaccines

Bavarian Nordic A/S recently announced it received a new contract of 440,000 doses to supply its MVA-BN® smallpox and mpox vaccine from an undisclosed European country. 

The Company confirmed all vaccines under this contract will be delivered in 2024.

Immediate access to these vaccines is essential since the mpox clade 1b outbreak is spreading in Africa.

Paul Chaplin, President & CEO of Bavarian Nordic, said in a press release on August 21, 2024, “Bavarian Nordic can still supply up to 10 million doses of our smallpox and mpox vaccine by the end of next year, with 2 million doses of this capacity available during the remaining part of this year.”

The MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic (JYNNEOS®, IMVANEX®, and IMVAMUNE®) is a non-replicating vaccine approved by several countries, including the United States.